- Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis
- HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
- Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 Antibody by the U.S. FDA
Hbm Holdings Ltd (2142:HKG.HZ) closed at 2.20, 152.87% above the 52 week low of 0.87 set on Nov 01, 2022.
0.87Nov 01 20226.11Apr 07 2022
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||1.74bn HKD|
|EPS (TTM)||-1.60 |
Data delayed at least 15 minutes, as of Mar 24 2023 08:08 BST.